KBI Biopharma Acquires Merck Biologics Operations

May 13, 2014

B3C Newswire

North Carolina-based KBI Biopharma signed an agreement with Merck & Co. to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014.

Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers. The acquisition will enable KBI to offer expanded microbial development and manufacturing services up to 1500L scale.

KBI is a contract development & manufacturing organization serving biopharmaceutical clients in the accelerated development of innovative medicines for global patients.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments